Asthma Therapeutics Market to surpass US$ 20.4 Billion by 2026

The Global Asthma Therapeutics Market, by Drug Class (Corticosteroids, Beta2-Agonists (Long-acting and Short-acting), Leukotriene Inhibitors, Long-acting Muscarinic Antagonists (LAMA), Interleukin Antagonists, Anti-immunoglobulin E (IgE) Agents, Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids, and Others), and Others), by Route of Administration (Oral, Inhalation, and Injection), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ XX million in 2017, and is projected to exhibit a CAGR of 1.9%, during the forecast period (2018 - 2026), as highlighted in a new report published by Coherent Market Insights.

Inhaler is a medical device, which facilitates the delivery of drug into body through lungs. It is mainly used in the treatment of respiratory diseases and disorders including asthma and chronic obstructive pulmonary disease (COPD). Inhaler divided into two types such as metered-dose inhaler and dry powder inhaler. Metered-dose inhalers are also called as aerosol-based inhalers. Dry powder inhalers are an alternative of metered-dose-inhalers.

Thus, increasing approval for inhalers by regulatory authorities is expected to drive the global asthma therapeutics market growth. For instance, in January 2019, Teva Pharmaceuticals Industries received U.S. Food and Drug Administration (USFDA) approval for its new (ProAir Digihaler) digital Inhaler. It is used for the improvement and treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). ProAir Digihaler is a first digital inhaler. It is multi-dose dry powder inhaler, which delivers 117 µg of Albuterol.

Furthermore, increasing number of clinical trials for treatment of asthma is expected to boost the global asthma therapeutics market value. For instance, in May 2018, Montefiore Medical Center initiated clinical study to evaluate the performance of ‘Adapting and Expanding the Algorithmic Software Tool (ASTHMAXcel App)’. This software teaches fundamental concept of asthma and its management. The study started in May 2018, and it is expected to complete in April 2020.

Browse 23 Market Data Tables and 19 Figures spread through 157 Pages and in-depth TOC on "Asthma Therapeutics Market, by Drug Class (Corticosteroids, Beta2-Agonists (Long-Acting and Short-Acting), Leukotriene Inhibitors, Long-Acting Muscarinic Antagonists (LAMA), Interleukin Antagonists, Anti-Immunoglobulin E (IgE) Agents, Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids, and Others), and Others), by Route of Administration (Oral, Inhalation, and Injection), and by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"

To know the latest trends and insights related to Global Asthma Therapeutics Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/asthma-therapeutics-market-2698

Key players in the market are focused on launching new products for asthma treatment. For instance, in May 2019, FindAir Company, launched its new Smart Inhaler Device FindAir One in Europe. It is used for treatment of asthma and chronic obstructive pulmonary disease (COPD). Moreover, in January 2019, FindAir One received CE marking for distribution in the Europe.

Moreover, consistent research and development activities are expected to drive the global asthma therapeutics market growth. For instance, in March 2018, Interregional Public Organization and Russian Respiratory Society initiated a clinical study to collect anonymous long-term evidences of severe asthma patients in Russia. The study is expected to complete in December 2022. Furthermore, in February 2019, University of Chicago initiated phase II clinical study on Azithromycin for treatment of asthma. This study is expected to complete in February 2020.

Key Takeaways of the Global Asthma Therapeutics Market:

• The global asthma therapeutics market is expected to witness a CAGR of 1.9% during the forecast period (2018–2026), owing to increasing product launches for improvement of respiratory disease including asthma and chronic obstructive pulmonary disease (COPD)
• Among the regions, North America is expected hold largest market share in global asthma therapeutics market over the forecast period, owing to rising prevalence of respiratory diseases in the U.S. For instance, according to Centers for Disease Control and Prevention (CDC), in 2016, around 24 million people, including over 6 million children, suffered from asthma in the U.S.
• Major players operating in the global asthma therapeutics market GlaxoSmithKline Plc., Philips Healthcare, AstraZeneca, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sanofi-Aventis SA, CareFusion Corporation, Sunovion Pharmaceuticals, Inc. Merck & Co., Inc., and Roche Diagnostics